Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomasz Zaremba

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Postepy Biochemii|September 29, 2010
[Oxidative DNA damage--analysis and clinical significance]Tomasz Zaremba, Ryszard Oliński
Anti-Cancer Agents in Medicinal Chemistry|September 28, 2007
PARP inhibitor development for systemic cancer targetingTomasz Zaremba, Nicola Jane Curtin
Mutation Research|August 17, 2010
Uracil in DNA--its biological significanceRyszard Olinski, Marek Jurgowiak, Tomasz Zaremba
Cancer Chemotherapy and Pharmacology|May 22, 2010
Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trialsTomasz Zaremba, Huw Thomas, Michael Cole, et al.
International Journal of Cancer|June 6, 2013
Variations in the mRNA expression of poly(ADP-ribose) polymerases, poly(ADP-ribose) glycohydrolase and ADP-ribosylhydrolase 3 in breast tumors and impact on clinical outcomeIvan Bieche, Vincent Pennaneach, Keltouma Driouch, et al.
The Biochemical Journal|March 26, 2011
Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteersTomasz Zaremba, Huw D Thomas, Michael Cole, et al.
Cellular and Molecular Life Sciences : CMLS|September 17, 2011
The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose) polymerase activity and responses to radiationCeleste Bolin, Mohammed-Tayyib Boudra, Marie Fernet, et al.
Cellular and Molecular Life Sciences : CMLS|October 23, 2014
PARP-2 depletion results in lower radiation cell survival but cell line-specific differences in poly(ADP-ribose) levelsMohammed-Tayyib Boudra, Celeste Bolin, Sara Chiker, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Postepy Biochemii|September 29, 2010
[Oxidative DNA damage--analysis and clinical significance]Tomasz Zaremba, Ryszard Oliński
Anti-Cancer Agents in Medicinal Chemistry|September 28, 2007
PARP inhibitor development for systemic cancer targetingTomasz Zaremba, Nicola Jane Curtin
Mutation Research|August 17, 2010
Uracil in DNA--its biological significanceRyszard Olinski, Marek Jurgowiak, Tomasz Zaremba
Cancer Chemotherapy and Pharmacology|May 22, 2010
Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trialsTomasz Zaremba, Huw Thomas, Michael Cole, et al.
International Journal of Cancer|June 6, 2013
Variations in the mRNA expression of poly(ADP-ribose) polymerases, poly(ADP-ribose) glycohydrolase and ADP-ribosylhydrolase 3 in breast tumors and impact on clinical outcomeIvan Bieche, Vincent Pennaneach, Keltouma Driouch, et al.
The Biochemical Journal|March 26, 2011
Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteersTomasz Zaremba, Huw D Thomas, Michael Cole, et al.
Cellular and Molecular Life Sciences : CMLS|September 17, 2011
The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose) polymerase activity and responses to radiationCeleste Bolin, Mohammed-Tayyib Boudra, Marie Fernet, et al.
Cellular and Molecular Life Sciences : CMLS|October 23, 2014
PARP-2 depletion results in lower radiation cell survival but cell line-specific differences in poly(ADP-ribose) levelsMohammed-Tayyib Boudra, Celeste Bolin, Sara Chiker, et al.
Pageof 1